Efficacy News and Research

RSS

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026

Base editing approach repairs deadly Dravet syndrome mutation in mice

Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of childhood epilepsy. After the edit, the mice have far fewer seizures and live much longer.

13 May 2026

Experts urge WHO to strengthen airborne virus precautionary measures

With three people dead and 11 cases from the recent hantavirus outbreak on a cruise ship, UMD's internationally renowned expert on airborne viruses, Dr. Don Milton, joins public health colleagues in an opinion piece in the British Medical Journal (BMJ) calling on the World Health Organization (WHO) to shift its default response to emerging respiratory viruses.

13 May 2026

Obesity drugs and surgery linked to greater fat-free mass loss

A new systematic review and meta-analysis of studies presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that diet and exercise interventions result in a lower proportion of fat-free mass loss compared with obesity surgery or obesity drugs among people undergoing a weight loss of 10% or more.

13 May 2026

New drug carrier improves cancer treatment by anchoring to tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, which means they need to stay near the diseased tissues long enough.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Rhein protects against intestinal injury in severe acute pancreatitis

Severe acute pancreatitis (SAP) remains one of the most formidable challenges in gastrointestinal emergency medicine.

13 May 2026

Implantable cytokine factories show promise against advanced ovarian cancer

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality.

12 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

Using AI to improve success rates of fecal microbiota transplants

MOZAIC leverages deep learning to optimize fecal microbiota transplantation, enhancing treatment efficacy through precise donor-recipient microbiome matching.

12 May 2026

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

INDIGO Biosciences today announced the launch of its Transrepression Assay Services, expanding the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway cross-talk, selective modulation, and transcription factor-mediated gene suppression.

From INDIGO Biosciences, Inc. 11 May 2026

Study compares two antibiotics in treating severe hemorrhagic bacterial pneumonia

Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant bacterium that can cause severe and life-threatening hemorrhagic pneumonia in individuals with weakened immune systems.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Targeted mitochondrial therapy accelerates healing of diabetic chronic wounds

Impaired mitophagy and the accumulation of damaged mitochondria are key drivers of endothelial cell (EC)dysfunction in diabetic wounds.

10 May 2026

Suppressing TGF-β signaling reactivates dormant bone cells to treat osteoporosis

Osteoporosis, a common skeletal disorder, is marked by reduced bone mass and deterioration of bone microarchitecture, making bones more porous and prone to fractures.

8 May 2026

New nanoparticles disable drug resistance to achieve complete tumor elimination

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) -- which is one of the leading reasons why chemotherapy fails in patients.

8 May 2026

The power of organoids in speeding up lifesaving drug development

Organoids are miniature tissue or organ models formed by stem cells (including pluripotent stem cells, tissue-specific adult stem cells, etc.) or progenitor cells in an in vitro three-dimensional culture system, which possess structural features and partial functions analogous to their corresponding in vivo organs. In 2009, the Hans Clevers laboratory developed the first intestinal organoid, marking the inception of organoid-based disease modeling.

8 May 2026

Eating eggs regularly reduces Alzheimer’s disease risk

Findings suggest that egg consumption is associated with lower Alzheimer's disease risk, supporting the need for further research on diet and brain health.

8 May 2026

Time-restricted eating helps with adherence in diabetes patients

Time-restricted eating shows promise for type 2 diabetes management, with family support and simple rules aiding adherence and metabolic health improvements.

8 May 2026